|
Frank L. Douglas, Ph.D., M.D., Executive Director, Center for Biomedical Innovation, Massachusetts Institute of Technology, former Executive Vice President of Aventis
Lee E. Babiss, Ph.D., Vice President, Preclinical R&D, F. Hoffmann La Roche Inc.
Marcel van Duin, Ph.D., Executive Director and Head, Department of Pharmacology, NV Organon
Prof. Camille Georges Wermuth, Faculty of Pharmacy, Louis Pasteur University, Strasbourg, and President and Chief Scientific Officer, Medicinal Chemistry, Prestwick Chemical
Andrew L. Hopkins, Ph.D., Associate Research Fellow, Knowledge Discovery, Pfizer Global R&D
Josep Prous, Jr., Ph.D., Executive Vice President, Prous Institute for Biomedical Research
Bryan Roth, MD., Ph.D., Professor, Department of Biochemistry, Comprehensive Cancer Center and National Institute of Mental Health Psychoactive Drug Screening Program, Case Western Reserve University Medical School
Louis A. Tartaglia, Ph.D., Senior Vice President and General Manager, Drug Repositioning & Selection, Gene Logic Inc.
Christopher A. Lipinski, Ph.D., Scientific Advisor, Melior Discovery and Adjunct Senior Research Fellow, Exploratory Medicinal Sciences, Pfizer Global R&D Groton Labs
Justin Lamb, Ph.D., Senior Scientist, Cancer Program, and Leader, Connectivity Map Project, Broad Institute of MIT and Harvard
John Overington, Ph.D., Vice President, Drug Discovery, Inpharmatica Ltd.
Rita Sattler, Ph.D., Department of Neurology, Johns Hopkins University
Peter X. Ellis, Ph.D., Executive Director, Sex Health and Urology, Pfizer
Harry C. Dietz, M.D., Investigator, Howard Hughes Medical Institute and Department of Pediatrics, Johns Hopkins University School of Medicine
Thomas Logan, Ph.D., Vice President, Business Development and Project Management, BTG International
Rudi Scherhag, Ph.D., Executive Vice President, Department of Project and Business Development, Heidelberg Pharma GmbH
|
